Compare AXP & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AXP | NVO |
|---|---|---|
| Founded | 1850 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 246.7B | 199.4B |
| IPO Year | 2005 | 2001 |
| Metric | AXP | NVO |
|---|---|---|
| Price | $308.39 | $38.65 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 30 | 14 |
| Target Price | ★ $371.12 | $46.15 |
| AVG Volume (30 Days) | 2.5M | ★ 11.5M |
| Earning Date | 10-23-2026 | 11-04-2026 |
| Dividend Yield | 1.23% | ★ 3.36% |
| EPS Growth | ★ 9.78 | N/A |
| EPS | ★ 8.81 | N/A |
| Revenue | ★ $27,819,000,000.00 | N/A |
| Revenue This Year | $18.66 | N/A |
| Revenue Next Year | $9.03 | $1.35 |
| P/E Ratio | $34.96 | ★ $13.60 |
| Revenue Growth | ★ 13.44 | N/A |
| 52 Week Low | $290.97 | $35.12 |
| 52 Week High | $387.49 | $64.16 |
| Indicator | AXP | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 42.24 | 36.02 |
| Support Level | $301.54 | $38.02 |
| Resistance Level | $319.24 | $39.58 |
| Average True Range (ATR) | 5.18 | 0.71 |
| MACD | 1.15 | 0.12 |
| Stochastic Oscillator | 55.14 | 40.00 |
American Express is a global financial institution, operating in about 130 countries, that provides consumers and businesses charge and credit card payment products. The company also operates a highly profitable merchant payment network. It operates in four segments: US consumer services, US commercial services, international card services, and global merchant and network services. In addition to payment products, the company's commercial business offers expense management tools, consulting services, and business loans.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.